ATHEROGENICS INC
S-1/A, EX-27.1, 2000-08-04
PHARMACEUTICAL PREPARATIONS
Previous: ATHEROGENICS INC, S-1/A, EX-23.01, 2000-08-04
Next: ATHEROGENICS INC, S-1/A, EX-27.2, 2000-08-04



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM OUR AUDITED
FINANCIAL STATEMENTS OF ATHEROGENICS, INC. AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED>

<S>                             <C>                    <C>                    <C>
<PERIOD-TYPE>                   YEAR                   YEAR                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997             DEC-31-1998             DEC-31-1999
<PERIOD-START>                             JAN-01-1997             JAN-01-1998             JAN-01-1999
<PERIOD-END>                               DEC-31-1997             DEC-31-1998             DEC-31-1999
<CASH>                                               0               3,683,423              13,409,450
<SECURITIES>                                         0                       0                       0
<RECEIVABLES>                                        0                       0                 791,653
<ALLOWANCES>                                         0                       0                       0
<INVENTORY>                                          0                       0                       0
<CURRENT-ASSETS>                                     0               4,942,445              14,290,722
<PP&E>                                               0               1,221,011               2,336,096
<DEPRECIATION>                                       0                (821,640)             (1,101,463)
<TOTAL-ASSETS>                                       0               5,341,816              15,717,214
<CURRENT-LIABILITIES>                                0               9,201,811               4,639,483
<BONDS>                                              0                       0                       0
                                0              14,704,449              38,711,491
                                          0                       0                       0
<COMMON>                                             0                 281,751               2,209,962
<OTHER-SE>                                           0             (19,009,507)            (31,016,687)
<TOTAL-LIABILITY-AND-EQUITY>                         0               5,341,816              15,717,214
<SALES>                                              0                       0                       0
<TOTAL-REVENUES>                                     0                       0               1,347,209
<CGS>                                                0                       0                       0
<TOTAL-COSTS>                                        0                       0                       0
<OTHER-EXPENSES>                             5,644,708              10,528,711              11,719,842
<LOSS-PROVISION>                                     0                       0                       0
<INTEREST-EXPENSE>                            (485,392)                205,130                  60,817
<INCOME-PRETAX>                             (5,159,316)            (10,733,841)            (10,433,250)
<INCOME-TAX>                                         0                       0                       0
<INCOME-CONTINUING>                         (5,159,316)            (10,733,841)            (10,433,250)
<DISCONTINUED>                                       0                       0                       0
<EXTRAORDINARY>                                      0                       0                       0
<CHANGES>                                            0                       0                       0
<NET-INCOME>                                (5,519,316)            (10,733,841)            (10,433,250)
<EPS-BASIC>                                      (2.25)                  (4.45)                  (4.27)
<EPS-DILUTED>                                    (2.25)                  (4.45)                  (4.27)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission